The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Key takeaways
- Compare Australian trading platforms that offer access to US markets so you can buy Bristol‑Myers Squibb (NYSE: BMY) shares directly.
- Watch for brokers with low foreign exchange and brokerage fees to reduce your overall trading costs on US stocks.
- Use the price and performance data on this page to decide whether now aligns with your investment goals before buying.
Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$57.39. During the previous open market day, the price has varied from a low of USD56.45 to a high of USD57.69. Bristol-Myers Squibb Company is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Bristol-Myers Squibb Company
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Bristol-Myers Squibb Company. Find the share by name or ticker symbol: BMY. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bristol-Myers Squibb Company reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$57.39, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Bristol-Myers Squibb Company, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Bristol-Myers Squibb Company. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Compare trading platforms to buy Bristol-Myers Squibb Company shares
Compare other products
We currently don't have that product, but here are others to consider:
How we picked theseFinder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
Have Bristol-Myers Squibb Company's shares ever split?
Bristol-Myers Squibb Company's shares were split on a 1000000:951777 basis on 6 August 2001. So if you had owned 951777 shares the day before the split, the next day you would own 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 4.8% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.
Bristol-Myers Squibb Company shares at a glance
Information last updated 2026-03-18.
| 52-week range | US$41.8826 - US$62.8864 |
|---|---|
| 50-day moving average | US$58.3182 |
| 200-day moving average | US$50.2281 |
| Target price | US$62.72 |
| PE ratio | 17.159 |
| Dividend yield | US$2.49 (4.17%) |
| Earnings per share (TTM) | US$3.46 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Bristol-Myers Squibb Company price performance over time
Historical closes compared with the last close of $57.39
| 1 week (2026-03-18) | -3.34% |
|---|---|
| 1 month (2026-02-25) | -6.38% |
| 3 months (2025-12-24) | 4.90% |
| 6 months (2025-09-25) | 32.20% |
| 1 year (2025-03-25) | -3.04% |
|---|---|
| 2 years (2024-03-25) | 9.84% |
| 3 years (2023-03-24) | -15.20% |
| 5 years (2021-03-25) | -8.60% |
Is it a good time to buy Bristol-Myers Squibb Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is it worth buying Bristol-Myers Squibb Company stock?
Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb Company's P/E ratio
Bristol-Myers Squibb Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Bristol-Myers Squibb Company shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Bristol-Myers Squibb Company's PEG ratio
Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2562. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bristol-Myers Squibb Company's EBITDA
Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$19.1 billion (£14.4 billion).
The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure stock profitability.
Bristol-Myers Squibb Company share price volatility
Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as US$41.8826 up to US$62.8864. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.266. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).
Bristol-Myers Squibb Company financials
| Revenue TTM | US$48.2 billion |
|---|---|
| Operating margin TTM | 28.16% |
| Gross profit TTM | US$35 billion |
| Return on assets TTM | 10.29% |
| Return on equity TTM | 40.44% |
| Profit margin | 14.64% |
| Book value | 9.073 |
| Market capitalisation | US$120.9 billion |
| EBITDA | US$19.1 billion |
TTM: trailing 12 months
Bristol-Myers Squibb Company share dividends
Dividend payout ratio: 40.65% of net profits
Recently Bristol-Myers Squibb Company has paid out, on average, around 40.65% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.22% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 4.22% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.49 per share.
While Bristol-Myers Squibb Company's payout ratio might seem fairly standard, it's worth remembering that Bristol-Myers Squibb Company may be investing much of the rest of its net profits in future growth.
Bristol-Myers Squibb Company's most recent dividend payout was on 30 April 2026. The latest dividend was paid out to all shareholders who bought their shares by 1 April 2026 (the "ex-dividend date").
Bristol-Myers Squibb Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Bristol-Myers Squibb Company's total ESG risk score
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Bristol-Myers Squibb Company's environmental score
Environmental score: 3.83/100
Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's social score
Social score: 18.82/100
Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bristol-Myers Squibb Company's governance score
Governance score: 14.02/100
Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bristol-Myers Squibb Company's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.16 |
|---|---|
| Total ESG percentile | 52.58 |
| Environmental score | 3.83 |
| Environmental score percentile | 4 |
| Social score | 18.82 |
| Social score percentile | 4 |
| Governance score | 14.02 |
| Governance score percentile | 4 |
| Level of controversy | 2 |
Bristol-Myers Squibb Company overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Frequently asked questions
Sources
More resources on Finder
Ask a question
More guides on Finder
-
Betashares Direct review
Pay zero brokerage when you invest in ASX ETFs using Betashares Direct.
-
Best performing stocks on the ASX
Top gainers included EQ Resources, Viva Energy Group and Elsight.
-
Sharesies review
Here's a detailed review of micro-investing app Sharesies plus its key features and pros and cons.
-
ASX lithium stocks
Lithium is a precious metal with increasing demand. Here’s what you should know before you invest.
-
What are the best AI stocks on the ASX in 2026? Stocks and ETFs to watch
Here's what investors should know before adding AI stocks to their portfolios.
-
Vanguard Personal Investor review
We took a look at the features and fees of the latest share trading platform.
-
How to invest in Nasdaq from Australia
Find out how you can invest in Nasdaq and compare a range of leading brokers that let you invest in US stocks cheaply and quickly.
-
How to invest in index funds in Australia
Index funds are a hot topic right now, but how do you actually invest in them?
-
Stake review: A trading platform for AU and US stocks
Stake is a trading platform for Australians who want value for money when trading. Gain access to one of the cheapest CHESS-sponsored and US trading platforms in Australia, and $3 brokerage in the US.
-
Totality (formerly Saxo) Australia review: Share trading platform
Totality allows you to trade over 60,000 instruments on 50 global stock exchanges and provides lower commissions for active traders.